STSE.Y Stock Overview
Designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Stratec SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.61 |
| 52 Week High | €8.61 |
| 52 Week Low | €8.61 |
| Beta | 0.14 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -55.50% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| STSE.Y | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | n/a | 2.3% | 2.9% |
| 1Y | n/a | 3.1% | 16.9% |
Return vs Industry: Insufficient data to determine how STSE.Y performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how STSE.Y performed against the US Market.
Price Volatility
| STSE.Y volatility | |
|---|---|
| STSE.Y Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: STSE.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine STSE.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 1,473 | Marcus Wolfinger | www.stratec.com |
Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers; and offers complex consumables for diagnostics and medical applications. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018.
Stratec SE Fundamentals Summary
| STSE.Y fundamental statistics | |
|---|---|
| Market cap | US$551.40m |
| Earnings (TTM) | US$15.93m |
| Revenue (TTM) | US$279.79m |
33.2x
P/E Ratio1.9x
P/S RatioIs STSE.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STSE.Y income statement (TTM) | |
|---|---|
| Revenue | €255.98m |
| Cost of Revenue | €186.66m |
| Gross Profit | €69.33m |
| Other Expenses | €54.75m |
| Earnings | €14.58m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 25, 2024
| Earnings per share (EPS) | 1.20 |
| Gross Margin | 27.08% |
| Net Profit Margin | 5.69% |
| Debt/Equity Ratio | 0% |
How did STSE.Y perform over the long term?
See historical performance and comparison